Business
Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the Mexican patent office has issued a notice of allowance for the Company's patent application covering its proprietary topical pain-relief technology.
About this update from Summit Hotel Properties, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Innocan's first fully-granted patent in Mexico","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Covers Innocan's proprietary cannabis-based pain relief topical","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Indication of Innocan's growing intellectual property portfolio","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":184,"olType":false},{"type":"text","content":"HERZLIYA, Israel and CALGARY, AB, May 6, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the Mexican patent office has issued a notice of allowance for the Company's patent application covering its proprietary topical pain-relief technology.","length":431,"tagName":"p"},{"type":"image","alt":"Innocan Pharma Logo","displaySize":"","headline":null,"caption":"Innocan Pharma Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":283,"url":"https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MQ_objxOFBZ.dAp8fl2HIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ5OTtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166","width":400,"height":283}}},{"type":"text","content":"This patent covers a groundbreaking formulation comprising the unique blending of cannabidiol with minerals to deliver fast-acting, targeted pain relief. Clinical studies have demonstrated noticeable pain reduction within 20 minutes of application. The approval of this patent represents a major milestone in Innocan's mission to advance next-generation topical therapeutic solutions.","length":388,"tagName":"p"},{"type":"text","content":"The Mexican allowance adds to previously granted counterpart patents in the United States, Russia, and Ukraine, and complements a growing portfolio of pending applications across various global jurisdictions. This development positions Innocan for early and strategic access to Latin American markets.","length":301,"tagName":"p"},{"type":"text","content":""We are very excited about the patent approval of our topical pain relief technology in Mexico," ...